Cedilla Therapeutics, Inc.

United States of America

Back to Profile

1-22 of 22 for Cedilla Therapeutics, Inc. Sort by
Query
Aggregations
Jurisdiction
        World 10
        Canada 7
        United States 5
Date
2024 11
2023 5
2022 6
IPC Class
C07D 487/10 - Spiro-condensed systems 9
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia 8
A61P 35/00 - Antineoplastic agents 7
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or 6
A61K 31/33 - Heterocyclic compounds 5
See more
Status
Pending 10
Registered / In Force 12
Found results for  patents

1.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Application Number 18274962
Status Pending
Filing Date 2022-01-28
First Publication Date 2024-05-30
Owner Cedilla Therapeutics, Inc. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Michowski, Wojtek
  • Porter, Jr., Dale A.
  • Ripper, Justin
  • Feutrill, John
  • Sherrill, John Paul
  • Blaisdell, Thomas P.

Abstract

The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

IPC Classes  ?

  • C07D 487/10 - Spiro-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

2.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Document Number 03262943
Status Pending
Filing Date 2023-07-28
Open to Public Date 2024-02-01
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Blaisdell, Thomas P.

IPC Classes  ?

  • A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
  • A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 227/02 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D 487/10 - Spiro-condensed systems

3.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Document Number 03263003
Status Pending
Filing Date 2023-07-28
Open to Public Date 2024-02-01
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Blaisdell, Thomas P.

IPC Classes  ?

  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61K 31/33 - Heterocyclic compounds
  • A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/503 - PyridazinesHydrogenated pyridazines spiro-condensed

4.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Document Number 03263008
Status Pending
Filing Date 2023-07-28
Open to Public Date 2024-02-01
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Blaisdell, Thomas P.

IPC Classes  ?

  • A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
  • A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 487/10 - Spiro-condensed systems

5.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Document Number 03263134
Status Pending
Filing Date 2023-07-28
Open to Public Date 2024-02-01
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Blaisdell, Thomas P.

IPC Classes  ?

  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61K 31/33 - Heterocyclic compounds
  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

6.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Application Number US2023071250
Publication Number 2024/026479
Status In Force
Filing Date 2023-07-28
Publication Date 2024-02-01
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Blaisdell, Thomas P.

Abstract

The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

IPC Classes  ?

  • C07D 487/10 - Spiro-condensed systems
  • A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
  • A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 35/00 - Antineoplastic agents

7.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Application Number US2023071252
Publication Number 2024/026481
Status In Force
Filing Date 2023-07-28
Publication Date 2024-02-01
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Blaisdell, Thomas P.

Abstract

The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

IPC Classes  ?

  • C07D 487/10 - Spiro-condensed systems
  • A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
  • A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 35/00 - Antineoplastic agents

8.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Application Number US2023071255
Publication Number 2024/026483
Status In Force
Filing Date 2023-07-28
Publication Date 2024-02-01
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise, Clare
  • Schwartz, Carl, Eric
  • Blaisdell, Thomas, P.

Abstract

The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

IPC Classes  ?

  • C07D 487/10 - Spiro-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • C07D 227/02 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
  • A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

9.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Application Number US2023071258
Publication Number 2024/026486
Status In Force
Filing Date 2023-07-28
Publication Date 2024-02-01
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Blaisdell, Thomas P.

Abstract

The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

IPC Classes  ?

  • A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
  • A61K 31/503 - PyridazinesHydrogenated pyridazines spiro-condensed
  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
  • A61K 31/33 - Heterocyclic compounds

10.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Document Number 03263133
Status Pending
Filing Date 2023-07-28
Open to Public Date 2024-02-01
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Blaisdell, Thomas P.

IPC Classes  ?

  • A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
  • A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 487/10 - Spiro-condensed systems

11.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Application Number US2023071256
Publication Number 2024/026484
Status In Force
Filing Date 2023-07-28
Publication Date 2024-02-01
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Blaisdell, Thomas P.

Abstract

The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

IPC Classes  ?

  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
  • A61K 31/33 - Heterocyclic compounds

12.

CDK2 inhibitors and methods of using the same

      
Application Number 17849321
Grant Number 12053459
Status In Force
Filing Date 2022-06-24
First Publication Date 2023-04-20
Grant Date 2024-08-06
Owner Cedilla Therapeutics, Inc. (Morocco)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Michowski, Wojtek
  • Porter, Jr., Dale A.
  • Ripper, Justin
  • Feutrill, John

Abstract

The present disclosure relates generally to Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and uses thereof in the inhibition of the activity of CDK2. The disclosure also provides pharmaceutically acceptable compositions comprising compounds disclosed herein and methods of using said compounds and compositions in the treatment of various disorders related to CDK2 activity.

IPC Classes  ?

  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
  • A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
  • A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
  • A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • C07D 471/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

13.

CDK2 inhibitors and methods of using the same

      
Application Number 17649269
Grant Number 12065445
Status In Force
Filing Date 2022-01-28
First Publication Date 2023-04-06
Grant Date 2024-08-20
Owner Cedilla Therapeutics, Inc. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Michowski, Wojtek
  • Porter, Jr., Dale A.
  • Ripper, Justin
  • Feutrill, John
  • Sherrill, John Paul
  • Blaisdell, Thomas P.

Abstract

The present disclosure provides compounds according to Formula I or a pharmaceutically acceptable salt thereof: wherein each variable is as defined and described herein, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

IPC Classes  ?

  • C07D 487/10 - Spiro-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

14.

TEAD INHIBITORS AND USES THEREOF

      
Application Number 17704126
Status Pending
Filing Date 2022-03-25
First Publication Date 2023-03-30
Owner Cedilla Therapeutics, Inc. (USA)
Inventor
  • Rennie, Glen Robert
  • Schwartz, C. Eric
  • Kirman, Louise
  • Porter, Dale
  • Song, Ling

Abstract

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

IPC Classes  ?

  • C07D 487/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • C07D 471/04 - Ortho-condensed systems
  • C07D 215/14 - Radicals substituted by oxygen atoms
  • C07D 239/74 - QuinazolinesHydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 215/233 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
  • C07D 471/14 - Ortho-condensed systems
  • C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

15.

TEAD INHIBITORS AND USES THEREOF

      
Application Number 17808868
Status Pending
Filing Date 2022-06-24
First Publication Date 2023-02-23
Owner Cedilla Therapeutics, Inc. (USA)
Inventor
  • Rennie, Glen Robert
  • Schwartz, C. Eric
  • Porter, Dale
  • Song, Ling

Abstract

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

IPC Classes  ?

  • C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
  • C07D 215/20 - Oxygen atoms
  • C07D 213/06 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07C 39/205 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic part, with unsaturation outside the rings

16.

TEAD INHIBITORS AND USES THEREOF

      
Application Number US2022038805
Publication Number 2023/009785
Status In Force
Filing Date 2022-07-29
Publication Date 2023-02-02
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Rennie, Glen, Robert
  • Schwartz, C., Eric
  • Kirman, Louise
  • Porter, Dale
  • Song, Ling

Abstract

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

IPC Classes  ?

  • A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
  • C07C 233/27 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
  • A61P 35/00 - Antineoplastic agents

17.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Document Number 03225439
Status Pending
Filing Date 2022-06-24
Open to Public Date 2022-12-29
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Michowski, Wojtek
  • Porter, Jr., Dale A.
  • Feutrill, John
  • Ripper, Justin

Abstract

The present disclosure relates generally to Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and uses thereof in the inhibition of the activity of CDK2. The disclosure also provides pharmaceutically acceptable compositions comprising compounds disclosed herein and methods of using said compounds and compositions in the treatment of various disorders related to CDK2 activity.

IPC Classes  ?

  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
  • A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
  • A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
  • A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61P 15/16 - Masculine contraceptives
  • A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 35/00 - Antineoplastic agents
  • A61P 37/00 - Drugs for immunological or allergic disorders
  • C07D 471/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

18.

TEAD INHIBITORS AND USES THEREOF

      
Application Number US2022034860
Publication Number 2022/272036
Status In Force
Filing Date 2022-06-24
Publication Date 2022-12-29
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Rennie, Glen Robert
  • Schwartz, C. Eric
  • Porter, Dale
  • Song, Ling

Abstract

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

IPC Classes  ?

  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
  • A61P 35/00 - Antineoplastic agents

19.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Application Number US2022034963
Publication Number 2022/272106
Status In Force
Filing Date 2022-06-24
Publication Date 2022-12-29
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Michowski, Wojtek
  • Porter, Jr., Dale A.
  • Feutrill, John
  • Ripper, Justin

Abstract

The present disclosure relates generally to Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and uses thereof in the inhibition of the activity of CDK2. The disclosure also provides pharmaceutically acceptable compositions comprising compounds disclosed herein and methods of using said compounds and compositions in the treatment of various disorders related to CDK2 activity.

IPC Classes  ?

  • A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
  • A61K 31/33 - Heterocyclic compounds
  • A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
  • A61K 31/00 - Medicinal preparations containing organic active ingredients

20.

TEAD INHIBITORS AND USES THEREOF

      
Application Number US2022021842
Publication Number 2022/204452
Status In Force
Filing Date 2022-03-25
Publication Date 2022-09-29
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Rennie, Glen Robert
  • Schwartz, C. Eric
  • Kirman, Louise
  • Porter, Dale
  • Song, Ling

Abstract

The present application relates to compounds of formula (I'), pharmaceutically acceptable compositions thereof, and methods of using the same. The compounds of formula I' are TEAD inhibitors, useful in the treatment of cancer.

IPC Classes  ?

  • A61P 35/00 - Antineoplastic agents
  • C07D 215/38 - Nitrogen atoms
  • C07D 215/48 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
  • C07D 217/02 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines
  • C07D 217/06 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
  • C07D 239/74 - QuinazolinesHydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
  • C07D 239/94 - Nitrogen atoms
  • C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
  • C07D 471/04 - Ortho-condensed systems
  • C07D 471/14 - Ortho-condensed systems
  • C07D 487/04 - Ortho-condensed systems
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
  • A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
  • A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
  • A61K 31/47 - QuinolinesIsoquinolines
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/52 - Purines, e.g. adenine

21.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Document Number 03208618
Status Pending
Filing Date 2022-01-28
Open to Public Date 2022-08-04
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Michowski, Wojtek
  • Porter, Dale A., Jr.
  • Ripper, Justin
  • Feutrill, John
  • Sherrill, John Paul
  • Blaisdell, Thomas P.

Abstract

The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

IPC Classes  ?

  • A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
  • A61K 31/415 - 1,2-Diazoles
  • A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
  • A61K 31/426 - 1,3-Thiazoles
  • A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 35/00 - Antineoplastic agents
  • A61P 37/00 - Drugs for immunological or allergic disorders
  • C07D 487/10 - Spiro-condensed systems

22.

CDK2 INHIBITORS AND METHODS OF USING THE SAME

      
Application Number US2022070409
Publication Number 2022/165513
Status In Force
Filing Date 2022-01-28
Publication Date 2022-08-04
Owner CEDILLA THERAPEUTICS, INC. (USA)
Inventor
  • Kirman, Louise Clare
  • Schwartz, Carl Eric
  • Michowski, Wojtek
  • Porter, Dale A., Jr.
  • Ripper, Justin
  • Feutrill, John
  • Sherrill, John Paul
  • Blaisdell, Thomas P.

Abstract

The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

IPC Classes  ?

  • A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
  • C07D 227/02 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D 403/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings
  • A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine